Showing 1741-1750 of 7030 results for "".
FDA Grants Interchangeability to HADLIMA
https://practicaldermatology.com/series/dermwire-tv/fda-grants-interchangeability-to-hadlima/35962/In this week's DermwireTV, the FDA grants full interchangeability to HADLIMA; new research shows the impact of UV exposure on global skin cancer cases; and coverage from Music City SCALE addresses barriers to patient access to new therapies.Nail Disease and JAK Inhibitor Safety
https://reachmd.com/programs/practical-dermatology/nail-disease-and-jak-inhibitor-safety/35897/Brad Glick, DO, talks about the basics of nail anatomy, physiology, disease presentation, and treatments, as well as the safety of JAK inhibitors, at Music City SCALE 2025.Rosacea Treatment Options and Strategies
https://reachmd.com/programs/practical-dermatology/rosacea-treatment-options-and-strategies/35893/Joel L. Cohen, MD, FAAD, and Hilary Baldwin, MD, talk at Music City SCALE 2025 about the latest treatment options for rosacea and strategies for getting patient buy-in.Medical Dermatology Highlights
https://reachmd.com/programs/practical-dermatology/medical-dermatology-highlights/35889/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, summarizes the various medical dermatology sessions he presented at Music City SCALE 2025.Sunscreen as Self-Care
https://practicaldermatology.com/series/c-suite-chats/sunscreen-as-self-care/33249/Arielle Moody, product developer at Mama Sol, talks about the importance of sunscreen in beauty routines and how her company is attempting to make it more appealing.Journal Club: A Comprehensive Update
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-a-comprehensive-update/32402/Practical Dermatology Editorial Board member Christopher Bunick, MD, FAAD, discusses the recent Lancet article "Atopic Dermatitis" with primary author Emma Guttman, MD, PhD. Guttman-Yassky E, Renert-Yuval Y, Brunner PM. Atopic dermatitis. Lancet. 2025;405(10478):583-596. doi: 10.1016/S0140-6736(24)0Novel PsO Drug Could Be 'Closest Perception of a Cure,' Dr. Strober Says at Maui Derm
https://reachmd.com/programs/practical-dermatology/novel-pso-drug-could-be-closest-perception-of-a-cure-dr-strober-says-at-maui-derm/32922/A novel monoclonal antibody targeting IL-23 for the treatment of psoriasis offers an extended half-life that will be a key differentiator for patients, according to Bruce Strober, MD, PhD.Journal Club: Pediatric Treatment Adherence
https://reachmd.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-pediatric-treatment-adherence/32401/Practical Dermatology Editorial Board members Lawrence Eichenfield, MD, FAAD, Jason Hawkes, MD, MS FAAD, discuss the article "Treatment Adherence in Pediatric Atopic Dermatitis: A Systemic Review," from Pediatric Dermatology as well as their favorite strategies for treatment adherence and the impactJournal Club: Dupilumab and Risk of Malignancy
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-dupilumab-and-risk-of-malignancy/32398/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, speaks with Matthew Zirwas, MD, about the Journal of Allergy and Clinical Immunology: In Practice article "Risk of malignancy associated with use of dupilumab versus other treatments in atopic dermatitis patients: A national databaseLaser and Energy Devices Session: Dr. Ross
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/laser-and-energy-devices-session-dr-ross/32682/E. Vic Ross, MD, discusses some of the basics and applications that he covered during "Lasers and Energy Devices Used to Treat Medical Problems: What's New in 2025" at Maui Derm 2025.